[go: up one dir, main page]

WO2025087879A3 - Suppressing the pi3kgamma/akt signalling pathway for the treatment of acute myeloid leukemia - Google Patents

Suppressing the pi3kgamma/akt signalling pathway for the treatment of acute myeloid leukemia Download PDF

Info

Publication number
WO2025087879A3
WO2025087879A3 PCT/EP2024/079767 EP2024079767W WO2025087879A3 WO 2025087879 A3 WO2025087879 A3 WO 2025087879A3 EP 2024079767 W EP2024079767 W EP 2024079767W WO 2025087879 A3 WO2025087879 A3 WO 2025087879A3
Authority
WO
WIPO (PCT)
Prior art keywords
aml
pik3cg
myeloid leukemia
acute myeloid
inventors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/EP2024/079767
Other languages
French (fr)
Other versions
WO2025087879A2 (en
Inventor
Alexandre PUISSANT
Kris Wood
Anthony Martin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Institut National de la Sante et de la Recherche Medicale INSERM
Ecole Nationale Superieure de Chimie de Montpellier ENSCM
Universite de Montpellier
Universite Paris Cite
Duke University
Original Assignee
Centre National de la Recherche Scientifique CNRS
Institut National de la Sante et de la Recherche Medicale INSERM
Ecole Nationale Superieure de Chimie de Montpellier ENSCM
Universite de Montpellier
Universite Paris Cite
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Institut National de la Sante et de la Recherche Medicale INSERM, Ecole Nationale Superieure de Chimie de Montpellier ENSCM, Universite de Montpellier, Universite Paris Cite, Duke University filed Critical Centre National de la Recherche Scientifique CNRS
Publication of WO2025087879A2 publication Critical patent/WO2025087879A2/en
Publication of WO2025087879A3 publication Critical patent/WO2025087879A3/en
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Dose-limiting toxicity poses a major limitation to the clinical utility of targeted cancer therapies, often arising from target engagement in non-malignant tissues. This obstacle can be minimized by targeting cancer dependencies driven by proteins with tissue- and/or tumor-restricted expression. Here, the inventors show that in acute myeloid leukemia (AML), suppression of the myeloid-restricted PIK3CG/p110γ-PIK3R5/p101 axis blocks AKT signaling, compromises cell fitness, and sensitizes to established AML therapies. Importantly, the inventors find that existing small molecule inhibitors against PIK3CG are insufficient to achieve a sustained longterm anti-leukemic effect. To address this concern, the inventors developed a proteolysis- targeting chimera (PROTAC) heterobifunctional molecule that specifically degrades PIK3CG and potently suppresses AML progression alone and in combination with venetoclax in human AML cell lines, primary AML patient samples, and syngeneic mouse models.
PCT/EP2024/079767 2023-10-23 2024-10-22 Suppressing the pi3kgamma/akt signalling pathway for the treatment of acute myeloid leukemia Pending WO2025087879A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP23306854 2023-10-23
EP23306854.3 2023-10-23

Publications (2)

Publication Number Publication Date
WO2025087879A2 WO2025087879A2 (en) 2025-05-01
WO2025087879A3 true WO2025087879A3 (en) 2025-06-19

Family

ID=88697555

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2024/079767 Pending WO2025087879A2 (en) 2023-10-23 2024-10-22 Suppressing the pi3kgamma/akt signalling pathway for the treatment of acute myeloid leukemia

Country Status (1)

Country Link
WO (1) WO2025087879A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018118598A1 (en) * 2016-12-23 2018-06-28 Arvinas, Inc. Compounds and methods for the targeted degradation of fetal liver kinase polypeptides
US20200121684A1 (en) * 2018-03-10 2020-04-23 Yale University Modulators of btk proteolysis and methods of use
WO2021242859A1 (en) * 2020-05-27 2021-12-02 Duke University Compositions and methods for sensitizing acute myeloid leukemias to chemotherapy
CN115778977A (en) * 2022-11-15 2023-03-14 众爱数字医疗科技(广东)有限公司 Application of antisense oligonucleotide in preparing medicine for treating acute myeloid leukemia

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6566131B1 (en) 2000-10-04 2003-05-20 Isis Pharmaceuticals, Inc. Antisense modulation of Smad6 expression
US6410323B1 (en) 1999-08-31 2002-06-25 Isis Pharmaceuticals, Inc. Antisense modulation of human Rho family gene expression
US6107091A (en) 1998-12-03 2000-08-22 Isis Pharmaceuticals Inc. Antisense inhibition of G-alpha-16 expression
US5981732A (en) 1998-12-04 1999-11-09 Isis Pharmaceuticals Inc. Antisense modulation of G-alpha-13 expression
US6046321A (en) 1999-04-09 2000-04-04 Isis Pharmaceuticals Inc. Antisense modulation of G-alpha-i1 expression
US6365354B1 (en) 2000-07-31 2002-04-02 Isis Pharmaceuticals, Inc. Antisense modulation of lysophospholipase I expression
AR031130A1 (en) 2000-09-20 2003-09-10 Abbott Lab PROMOTING N-ACILSULFONAMIDS OF APOPTOSIS
US6566135B1 (en) 2000-10-04 2003-05-20 Isis Pharmaceuticals, Inc. Antisense modulation of caspase 6 expression
US20040092561A1 (en) 2002-11-07 2004-05-13 Thomas Ruckle Azolidinone-vinyl fused -benzene derivatives
PT2042504E (en) 2002-09-30 2011-09-07 Bayer Schering Pharma Ag Fused azole-pyrimidine derivatives
WO2004052373A1 (en) 2002-12-06 2004-06-24 Warner-Lambert Company Llc Benzoxazin-3-ones and derivatives thereof as inhibitors of pi3k
AU2003303231A1 (en) 2002-12-20 2004-07-14 Warner-Lambert Company Llc Benzoxazines and derivatives thereof as inhibitors of pi3ks
JP2006526614A (en) 2003-06-05 2006-11-24 ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー 3-Arylsulfanyl and 3-heteroarylsulfanyl-substituted benzo [b] thiophenes as therapeutic agents
EP1644360A1 (en) 2003-06-05 2006-04-12 Warner-Lambert Company LLC 3-substituted indoles and derivatives thereof as therapeutic agents
ATE365735T1 (en) 2003-06-05 2007-07-15 Warner Lambert Co CYCLOALKYLSULFANYL-SUBSTITUTED BENZO BÖTHIOPHENE AS THERAPEUTIC AGENTS
US20040259926A1 (en) 2003-06-05 2004-12-23 Bruendl Michelle M. 3-Aryloxy and 3-heteroaryloxy substituted benzo[b]thiophenes as therapeutic agents
JP2006526606A (en) 2003-06-05 2006-11-24 ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー Cycloalkyl and heterocycloalkyl substituted benzothiophenes as therapeutic agents
BRPI0411098A (en) 2003-06-05 2006-07-18 Warner Lambert Co benzofuranocarboxamides, with pi3k activity, as therapeutic agents
US7767684B2 (en) 2003-11-13 2010-08-03 Abbott Laboratories Apoptosis promoters
WO2005049593A2 (en) 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
US7642260B2 (en) 2003-11-13 2010-01-05 Abbott Laboratories, Inc. Apoptosis promoters
US7973161B2 (en) 2003-11-13 2011-07-05 Abbott Laboratories Apoptosis promoters
US7851637B2 (en) 2004-06-17 2010-12-14 Infinity Pharmaceuticals, Inc. Compounds and methods for inhibiting the interaction of BCL proteins with binding partners
US7842815B2 (en) 2004-06-17 2010-11-30 Infinity Pharmaceuticals, Inc. Compounds and methods for inhibiting the interaction of BCL proteins with binding partners
US8624027B2 (en) 2005-05-12 2014-01-07 Abbvie Inc. Combination therapy for treating cancer and diagnostic assays for use therein
DK1888550T3 (en) 2005-05-12 2014-09-29 Abbvie Bahamas Ltd Apoptosis promoters
WO2006127364A1 (en) 2005-05-24 2006-11-30 Abbott Laboratories Apoptosis promoters
US8168784B2 (en) 2008-06-20 2012-05-01 Abbott Laboratories Processes to make apoptosis promoters
CN102325531B (en) 2008-12-19 2014-04-02 健泰科生物技术公司 Compounds and methods of use
TWI535712B (en) 2010-08-06 2016-06-01 阿斯特捷利康公司 Chemical compounds
CN105246882A (en) 2013-01-16 2016-01-13 密执安大学评议会 BCL-2/Bcl-xL inhibitors and methods of treatment using said inhibitors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018118598A1 (en) * 2016-12-23 2018-06-28 Arvinas, Inc. Compounds and methods for the targeted degradation of fetal liver kinase polypeptides
US20200121684A1 (en) * 2018-03-10 2020-04-23 Yale University Modulators of btk proteolysis and methods of use
WO2021242859A1 (en) * 2020-05-27 2021-12-02 Duke University Compositions and methods for sensitizing acute myeloid leukemias to chemotherapy
CN115778977A (en) * 2022-11-15 2023-03-14 众爱数字医疗科技(广东)有限公司 Application of antisense oligonucleotide in preparing medicine for treating acute myeloid leukemia

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BENETATOS LEONIDAS ET AL: "The crosstalk between long non-coding RNAs and PI3K in cancer", MEDICAL ONCOLOGY, SCIENCE AND TECHNOLOGY LETTERS, NORTHWOOD, GB, vol. 34, no. 3, 7 February 2017 (2017-02-07), pages 1 - 13, XP036230795, ISSN: 1357-0560, [retrieved on 20170207], DOI: 10.1007/S12032-017-0897-2 *
BIANCHI MARCO E ET AL: "The Chemokine Receptor CXCR4 in Cell Proliferation and Tissue Regeneration", FRONTIERS IN IMMUNOLOGY, vol. 11, 28 August 2020 (2020-08-28), Lausanne, CH, XP093174606, ISSN: 1664-3224, DOI: 10.3389/fimmu.2020.02109 *
DREW SAMUEL L ET AL: "Discovery of Potent and Selective PI3K[gamma] Inhibitors", vol. 63, no. 19, 31 August 2020 (2020-08-31), US, pages 11235 - 11257, XP093174733, ISSN: 0022-2623, Retrieved from the Internet <URL:http://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.0c01203> [retrieved on 20240613], DOI: 10.1021/acs.jmedchem.0c01203 *
HAO LONGHUI ET AL: "LncRNA-MALAT1: A Key Participant in the Occurrence and Development of Cancer", MOLECULES, vol. 28, no. 5, 24 February 2023 (2023-02-24), CH, pages 2126, XP093174712, ISSN: 1420-3049, DOI: 10.3390/molecules28052126 *
LANDRY BREANNE ET AL: "Targeting CXCR4/SDF-1 axis by lipopolymer complexes of siRNA in acute myeloid leukemia", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 224, 30 December 2015 (2015-12-30), pages 8 - 21, XP029411429, ISSN: 0168-3659, DOI: 10.1016/J.JCONREL.2015.12.052 *
MENG DANDAN ET AL: "Development of PI3K inhibitors: Advances in clinical trials and new strategies (Review)", PHARMACOLOGICAL RESEARCH, ELSEVIER, AMSTERDAM, NL, vol. 173, 20 September 2021 (2021-09-20), XP086834820, ISSN: 1043-6618, [retrieved on 20210920], DOI: 10.1016/J.PHRS.2021.105900 *
RAHMANI MOHAMED ET AL: "Cotargeting BCL-2 and PI3K Induces BAX-Dependent Mitochondrial Apoptosis in AML Cells", vol. 78, no. 11, 1 June 2018 (2018-06-01), pages 3075 - 3086, XP055847210, ISSN: 0008-5472, Retrieved from the Internet <URL:https://cancerres.aacrjournals.org/content/canres/78/11/3075.full.pdf> [retrieved on 20240613], DOI: 10.1158/0008-5472.CAN-17-3024 *

Also Published As

Publication number Publication date
WO2025087879A2 (en) 2025-05-01

Similar Documents

Publication Publication Date Title
Filonenko et al. Photodynamic therapy in clinical practice
MXPA05004778A (en) Methods of using and compositions comprising immunomudulatory compounds for the treatment and management of myeloproliferative diseases.
MX2009010929A (en) Combination therapies comprising quinoxaline inhibitors of pi3k-alpha for use in the treatment of cancer.
TW200722083A (en) Combinations and methods of using an indolinone compound
MX2024012131A (en) Pharmaceutical composition, use thereof, and method for treating cancer
MX2025000105A (en) KRAS G12C INHIBITOR FOR THE TREATMENT OF CANCER
CA3254199A1 (en) Methods of medical treatment with sur1-trpm4 channel inhibitors
ATE543492T1 (en) TREATMENT OF LUNG CANCER
CA3250274A1 (en) Use of alc1 inhibitors and synergy with parpi
BRPI0413410A (en) coadministration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer
WO2025087879A3 (en) Suppressing the pi3kgamma/akt signalling pathway for the treatment of acute myeloid leukemia
Khalikova et al. Regulation of activity of cathepsins B, L, and D in murine lymphosarcoma model at a combined treatment with cyclophosphamide and yeast polysaccharide
MX2025001673A (en) Combination of anticancer agents comprising a bifunctional compound with g12d mutant kras inhibitory activity
Zhou et al. Toll-like receptor 5 agonist inhibition of growth of A549 lung cancer cells in vivo in a Myd88 dependent manner.
MX2025001671A (en) Combination of anticancer agents comprising a bifunctional compound with g12d mutant kras inhibitory activity
BRPI0416266A (en) method for treating, preventing and / or controlling an asbestos-related disease or disorder in a patient
WO2020198662A8 (en) Clec9a-based chimeric protein complexes
WO2019241641A3 (en) Cancer treatment methods
Singh et al. Role of ozone therapy and cancer: myth or reality
WO2024097446A3 (en) Theranostic compounds targeting granzyme b
AU2013214731A1 (en) Compositions comprising NDGA derivatives and sorafenib and their use in treatment of cancer
RU2443423C2 (en) Method of postoperative therapy of non-muscle invasive bladder cancer
WO2024102894A3 (en) Methods for treating monge&#39;s disease
BRPI0418798A (en) methods of treating or preventing, and controlling, a myeloproliferative disease, reducing or preventing an adverse effect, increasing the therapeutic efficacy of a myeloproliferative disease treatment, pharmaceutical composition, and kit
JP2021533107A (en) Combination therapy to treat cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24793817

Country of ref document: EP

Kind code of ref document: A2